About Transdermal Diagnostics
Transdermal Diagnostics is a company based in Bath (United Kingdom) founded in 2021 by Richard Guy, Adelina Ilie, and Luca Lipani.. Transdermal Diagnostics has raised $919.88 thousand across 2 funding rounds from investors including Gov.uk, Qubis and Immetric. The company has 2 employees as of August 31, 2022. Transdermal Diagnostics offers products and services including Continuous Glucose Monitor, Companion App, and Adhesive Skin Patch. Transdermal Diagnostics operates in a competitive market with competitors including Dexcom, Livongo, Bigfoot Biomedical, Senseonics and One Drop, among others.
- Headquarter Bath, United Kingdom
- Employees 2 as on 31 Aug, 2022
- Founders Richard Guy, Adelina Ilie, Luca Lipani
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Transdermal Diagnostics Ltd
- Date of Incorporation 16 Aug, 2021
- Jurisdiction BATH, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$919.88 K (USD)
in 2 rounds
-
Latest Funding Round
$344.96 K (USD), Grant
Sep 06, 2022
-
Investors
Gov.uk
& 6 more
-
Employee Count
2
as on Aug 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Transdermal Diagnostics
Transdermal Diagnostics offers a comprehensive portfolio of products and services, including Continuous Glucose Monitor, Companion App, and Adhesive Skin Patch. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Needle-free device for real-time glucose monitoring via skin patch and app.
App for wireless data communication from wearable device to smartphone.
Patch that draws biological substances for non-invasive health tracking.
Unlock access to complete
Unlock access to complete
Funding Insights of Transdermal Diagnostics
Transdermal Diagnostics has successfully raised a total of $919.88K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $344.96 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $344,955
-
First Round
First Round
(06 Sep 2022)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Seed - Transdermal Diagnostics | Valuation | Qubis | |
| Sep, 2022 | Amount | Grant - Transdermal Diagnostics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Transdermal Diagnostics
Transdermal Diagnostics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Qubis and Immetric. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Qubis is engaged in commercializing academic research from Queen's University.
|
Founded Year | Domain | Location | |
|
Early-stage capital and support are provided to deep-tech start-ups by Immetric.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Transdermal Diagnostics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Transdermal Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Transdermal Diagnostics Comparisons
Competitors of Transdermal Diagnostics
Transdermal Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Dexcom, Livongo, Bigfoot Biomedical, Senseonics and One Drop, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable glucose monitoring patches are provided for real-time data tracking.
|
|
| domain | founded_year | HQ Location |
Provider of smart devices for diabetes management for patients and doctors
|
|
| domain | founded_year | HQ Location |
Developer of a closed-loop automated insulin delivery system
|
|
| domain | founded_year | HQ Location |
Implantable continuous glucose monitoring systems are provided for diabetes management.
|
|
| domain | founded_year | HQ Location |
Provider of workforce healthcare solutions
|
|
| domain | founded_year | HQ Location |
Gamified apps for diabetes management and therapy are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Transdermal Diagnostics
When was Transdermal Diagnostics founded?
Transdermal Diagnostics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Transdermal Diagnostics located?
Transdermal Diagnostics is headquartered in Bath, United Kingdom. It is registered at Bath, Somerset, United Kingdom.
Who is the current CEO of Transdermal Diagnostics?
Luca Lipani is the current CEO of Transdermal Diagnostics. They have also founded this company.
Is Transdermal Diagnostics a funded company?
Transdermal Diagnostics is a funded company, having raised a total of $919.88K across 2 funding rounds to date. The company's 1st funding round was a Seed of $919.88K, raised on Sep 06, 2022.
How many employees does Transdermal Diagnostics have?
As of Aug 31, 2022, the latest employee count at Transdermal Diagnostics is 2.
What does Transdermal Diagnostics do?
Transdermal Diagnostics was founded in 2021 in Bath, United Kingdom. Operations focus on the medtech sector, where a non-invasive continuous glucose monitoring system is developed for chronic conditions, beginning with diabetes. A disposable adhesive skin patch and rechargeable transmitter are offered to enable needle-free monitoring. The companys activities are centered on advancing accessible diagnostic solutions in healthcare.
Who are the top competitors of Transdermal Diagnostics?
Transdermal Diagnostics's top competitors include Dexcom, Senseonics and Bigfoot Biomedical.
What products or services does Transdermal Diagnostics offer?
Transdermal Diagnostics offers Continuous Glucose Monitor, Companion App, and Adhesive Skin Patch.
Who are Transdermal Diagnostics's investors?
Transdermal Diagnostics has 7 investors. Key investors include Gov.uk, Qubis, Immetric, Bristol Private Equity Club, and Science Angel Syndicate.